isoxazoles has been researched along with celecoxib in 97 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.03) | 18.2507 |
| 2000's | 72 (74.23) | 29.6817 |
| 2010's | 19 (19.59) | 24.3611 |
| 2020's | 5 (5.15) | 2.80 |
| Authors | Studies |
|---|---|
| Arriola, ER; Lee, NP | 1 |
| Infante, R; Lahita, RG | 1 |
| Chong, BS; Lowder, DM; Luong, BT | 1 |
| Simon, LS; Yocum, D | 1 |
| Gierse, JK; Isakson, PC; Kiefer, JR; Koboldt, CM; Kurumbail, RG; Moreland, KT; Seibert, K; Walker, MC | 1 |
| Wasko, MC; Wildy, KS | 1 |
| Ouellet, M; Percival, MD; Riendeau, D | 1 |
| FitzGerald, GA | 2 |
| Hardy, KJ; McMurray, RW | 1 |
| Hayes, EC; Rock, JA | 1 |
| Rowbotham, DJ | 1 |
| Gierse, JK; Hood, WF; Isakson, PC; Kiefer, JR; Kurumbail, RG; Monahan, JB; Seibert, K | 1 |
| Carter, J; Gierse, J; Hood, B; Isakson, P; Kiefer, J; Koboldt, C; Kurumbail, R; Marnett, L; Monahan, J; Moreland, K; Pawlitz, J; Pierce, J; Rowlinson, S; Seibert, K; Stegeman, R; Stevens, A; Talley, J; Walker, M | 1 |
| Boehncke, WH; Gibbs, BF | 1 |
| Laskin, B; Pashos, C; Peña, B; Stephens, J; Wong, J | 1 |
| Burian, M; Geisslinger, G | 1 |
| Blumenthal, M; Chen, TC; Kardosh, A; Schönthal, AH; Wang, WJ | 1 |
| Casini, A; Heine, A; Klebe, G; Kuhn, D; Scozzafava, A; Supuran, CT; Weber, A | 1 |
| Møiniche, S; Rømsing, J | 1 |
| Chan, VS | 1 |
| Benoit, V; de Leval, X; Dogné, JM; Frederich, M; Julémont, F; Pirotte, B | 1 |
| Boggie, DT; Delattre, ML; Morreale, AP; Plowman, BK; Schaefer, MG; Tran, F | 1 |
| Dahlborg, R; Day, CA; Jacob, RF; Mason, RP; Walter, MF; Weng, Y | 1 |
| Topol, EJ | 1 |
| Meena, S; Nagaraju, D; Rao, AR; Rao, RN | 1 |
| Furberg, CD; Psaty, BM | 1 |
| Drazen, JM | 1 |
| Wadman, M | 2 |
| Couzin, J | 1 |
| Okie, S | 1 |
| Romanovsky, AA | 1 |
| Cotter, J; Wooltorton, E | 1 |
| Vanchieri, C | 1 |
| Albini, A; Noonan, DM | 1 |
| Hochberg, MC | 1 |
| Mullangi, R; Pavan Kumar, VV; Ramani, AV; Srinivas, NR; Vinu, MC | 1 |
| Epstein, RA | 1 |
| Cohen, JS | 1 |
| Cantilena, LR; Carlsson, U; Hammarström, P; Knudsen, JF; Sokol, GH | 1 |
| Bonnel, R; Brinker, A; Governale, L; Karwoski, C; La Grenade, L; Lee, L; Weaver, J | 1 |
| Meechan, J | 1 |
| Epstein, J; Klasser, GD | 1 |
| D'Ambrosio, K; De Simone, G; Di Fiore, A; Pedone, C; Scozzafava, A; Supuran, CT | 1 |
| Gherardi, CR | 1 |
| Fraunfelder, FW; Mehelas, TJ; Solomon, J | 1 |
| Dogné, JM; Hanson, J; Pratico, D; Supuran, C | 1 |
| Ciddi, V; Keshetty, S; Molmoori, V; Venisetty, RK | 1 |
| Bhatia, S; Seedher, N | 1 |
| Furberg, CD | 1 |
| Bohn, L; Sadée, W | 1 |
| Macrì, R; Manfredi, C | 1 |
| Abdalla, H; Buckley, E; Butler, M; Iohom, G; Larney, V; O'Brien, J; Shorten, GD; Szarvas, S | 1 |
| Deray, G; Montalescot, G; Sibilia, J | 1 |
| Deray, G; Héloire, F; Valat, JP | 1 |
| Jugdutt, BI | 1 |
| Macedo, GM; Medeiros, BA; Nobre-e-Souza, MA; Palheta-Junior, RC; Santos, AA; Santos, CL; Souza, MH; Troncon, LE | 1 |
| Gajraj, NM | 1 |
| Tabrizchi, R | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Bombardier, C; Coombs, JH; Copley-Merriman, C; Evans, C; Katz, N; Markman, J; Robbins, J; Simon, LS; West, C | 1 |
| Arguelles, J; Cobo, J; Costales, M; de Carlos, F; Garcia, MA; Perillan, C; Vijande, M | 1 |
| Chen, E; Li, C; Maguluri, S; Recchia, FM | 1 |
| DeAngelis, CD; Thornton, JP | 1 |
| Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J | 1 |
| Boutary, M; Dorr, LD; Long, WT; Raya, J; Sirianni, LE | 1 |
| Fujikawa, Y; Itonaga, I; Kawashima, M; Takita, C; Tsumura, H | 1 |
| Simon, LS; White, WB | 1 |
| Mateos, JL | 1 |
| Elliott, WJ | 1 |
| Intapan, T; Ittichaikulthol, W; Kositchaiwat, C; Prachanpanich, N | 1 |
| Ashok, V; Dash, C; Rohan, TE; Sprafka, JM; Terry, PD | 1 |
| Honjo, H; Iwamoto, K; Uwai, Y | 1 |
| Dávila, I; González, A; Laffond, E; Moreno, E; Muñoz-Bellido, F; Ponce, V | 1 |
| Baber, C; McDonnell, NJ; Nathan, EA; Paech, MJ; Sinha, A | 1 |
| Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y | 1 |
| Li, J; Li, N; Peng, N; Yang, X | 1 |
| Balbontín-Ayala, F; Cañigral, A; Carlos, Fd; Cobo, T; Fernández-González, FJ; Fernández-Vázquez, JP; Gonzalo-Orden, JM; Sánchez-Lasheras, F; Vega, JA | 1 |
| Hansen, SH; Skonberg, C; Syed, M | 1 |
| Supuran, CT | 1 |
| Katchamart, W; Suwanawiboon, B; Tantayakom, P; Teerawattananon, C | 1 |
| Bian, Y; Feng, B; Jiang, J; Lin, J; Pei, F; Shen, B; Sun, T; Wang, W; Weng, X; Yan, S; Zhang, M; Zhuang, Q | 1 |
| Filippini-de Moor, GP; Steegers, MA; van Helmond, N; Vissers, KC; Wilder-Smith, OH | 1 |
| Cheng, L; Long, HT; Sun, BH; Zhao, SS; Zhu, Y | 1 |
| Cai, W; Fan, J; Tang, J; Yao, Y; Yin, G; Zhou, W | 1 |
| Pei, F; Shen, B; Si, H; Weng, X; Wu, Y; Yang, T; Zeng, Y | 1 |
| Cooper, AR; Dileep Kumar, JS; Mann, JJ; Matthew, J; Parsey, RV; Prabhakaran, J; Rubin-Falcone, H; Simpson, NR; Underwood, M; Zanderigo, F | 1 |
| Bian, Y; Dong, Y; Fan, Y; Feng, B; Gao, N; Jin, J; Li, Y; Lin, J; Pei, F; Peng, H; Qian, W; Shen, B; Sun, T; Tao, L; Wang, W; Weng, X; Yan, S; Zhang, M; Zhuang, Q | 1 |
| Huang, L; Huang, Z; Jia, X; Liu, L; Ma, X; Tang, C; Wan, X; Wang, R; Zhang, M | 1 |
| Hu, XG; Jiang, W; Pang, JY; Wan, C; Zhang, XW | 1 |
| Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K | 1 |
| Chaibhuddanugul, N; Laoruengthana, A; Malisorn, S; Pongpirul, K; Rattanaprichavej, P; Tangsripong, P | 1 |
27 review(s) available for isoxazoles and celecoxib
| Article | Year |
|---|---|
Treatment advances in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Etanercept; Female; Humans; Immunoglobulin G; Isoxazoles; Leflunomide; Male; Prognosis; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides; Treatment Outcome | 1999 |
Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Lactones; Leflunomide; Male; Middle Aged; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides; Sulfones | 2000 |
Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Drug Interactions; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Male; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides | 2000 |
New and future drug therapies for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; CD40 Antigens; Celecoxib; Etanercept; Forecasting; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides | 2000 |
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Etanercept; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Lactones; Leflunomide; Methotrexate; Osteoarthritis; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfasalazine; Sulfonamides; Sulfones | 2001 |
Cox-2 inhibitors: today and tomorrow.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Research; Sulfonamides; Sulfones | 2002 |
COX-2 inhibitors and their role in gynecology.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Administration Schedule; Dysmenorrhea; Endometriosis; Female; Genital Diseases, Female; Humans; Infertility, Female; Isoenzymes; Isoxazoles; Labor, Obstetric; Membrane Proteins; Menorrhagia; Menstrual Cycle; Ovary; Ovulation; Pain; Polycystic Ovary Syndrome; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2002 |
COX-2-selective inhibitors: clinical relevance in surgical and acute pain.
Topics: Acute Disease; Analgesics; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Pain; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2002 |
The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost of Illness; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quality of Life; Sulfonamides; Sulfones; Treatment Outcome | 2003 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pain; Pain, Postoperative; Placebos; Pyrazoles; Sulfonamides; Sulfones | 2003 |
A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Pain Measurement; Pain, Postoperative; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Treatment Outcome | 2004 |
A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2004 |
First and second generations of COX-2 selective inhibitors.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2004 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Peptic Ulcer; Pyrazoles; Sulfonamides; Sulfones; Toothache | 2005 |
Coxibs and cardiovascular side-effects: from light to shadow.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Isoxazoles; Lactones; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones; Thromboxane A2 | 2006 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Pain, Postoperative; Pyrazoles; Sulfonamides; Treatment Outcome | 2007 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
COX-2 selective inhibitors and heart health.
Topics: Adult; Cardiovascular Diseases; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones | 2005 |
[Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Routes; Evidence-Based Medicine; Humans; Inflammation; Isoxazoles; Pain; Pain Measurement; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Treatment Outcome | 2010 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones | 2014 |
Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Bone Remodeling; Celecoxib; Clodronic Acid; Diclofenac; Diphosphonates; Humans; Imidazoles; Interferon-gamma; Isoxazoles; Lactones; Mice; Orthodontic Anchorage Procedures; Osteoclasts; Osteoprotegerin; Pamidronate; Rats; Resveratrol; Stilbenes; Sulfones; Tooth Mobility; Tooth Movement Techniques; Zoledronic Acid | 2015 |
Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.
Topics: Acetazolamide; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Antibodies, Monoclonal; Anticonvulsants; Antineoplastic Agents; Benzodiazepines; Carbonic Anhydrase Inhibitors; Celecoxib; Clinical Trials as Topic; Contraindications; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fructose; Humans; Isoxazoles; Methazolamide; Phenobarbital; Sulfanilamide; Sulfanilamides; Sulfonamides; Sulfonic Acids; Thiazines; Thiophenes; Topiramate; Zonisamide | 2016 |
Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: A systematic review and meta-analysis.
Topics: Blood Loss, Surgical; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Isoxazoles; Postoperative Hemorrhage; Pyridines; Risk Factors; Sulfones | 2017 |
14 trial(s) available for isoxazoles and celecoxib
| Article | Year |
|---|---|
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxygenase 2; Drug Utilization Review; Endpoint Determination; Female; Hospitals, Veterans; Humans; Isoenzymes; Isoxazoles; Lactones; Male; Membrane Proteins; Osteoarthritis; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Therapeutic Equivalency | 2004 |
COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ibuprofen; Injections, Intravenous; Isoxazoles; Lactones; Pain, Postoperative; Preanesthetic Medication; Prodrugs; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction | 2006 |
Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study.
Topics: Adult; Area Under Curve; Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Half-Life; Humans; Isoxazoles; Male; Pyrazoles; Sulfonamides | 2006 |
The associations between severity of early postoperative pain, chronic postsurgical pain and plasma concentration of stable nitric oxide products after breast surgery.
Topics: Acetaminophen; Adult; Aged; Analgesia; Anxiety; Breast Neoplasms; Bupivacaine; Celecoxib; Chronic Disease; Depression; Dextropropoxyphene; Diclofenac; Female; Humans; Isoxazoles; Mastectomy; Middle Aged; Morphine; Nerve Block; Nitric Oxide; Nociceptors; Pain Measurement; Pain, Postoperative; Pyrazoles; Sulfonamides | 2006 |
Multimodal analgesia without parenteral narcotics for total knee arthroplasty.
Topics: Administration, Oral; Amides; Analgesia, Epidural; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthetics, Local; Arthroplasty, Replacement, Knee; Aspirin; Catheters, Indwelling; Celecoxib; Drug Administration Schedule; Drug Therapy, Combination; Femoral Nerve; Hip Joint; Humans; Injections, Intra-Articular; Isoxazoles; Ketorolac; Nerve Block; Pain Measurement; Pain, Postoperative; Prospective Studies; Pyrazoles; Ropivacaine; Sulfonamides | 2008 |
The post-operative analgesic efficacy of celecoxib compared with placebo and parecoxib after total hip or knee arthroplasty.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analgesia; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Isoxazoles; Male; Middle Aged; Pain, Postoperative; Postoperative Period; Pyrazoles; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
A randomised controlled trial of parecoxib, celecoxib and paracetamol as adjuncts to patient-controlled epidural analgesia after caesarean delivery.
Topics: Acetaminophen; Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Celecoxib; Cesarean Section; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Isoxazoles; Pregnancy; Pyrazoles; Sulfonamides | 2014 |
Effect of cyclooxygenase-2-specific inhibitors on postoperative analgesia after major open abdominal surgery.
Topics: Abdomen; Analgesia, Patient-Controlled; Analgesics, Opioid; Analysis of Variance; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Elective Surgical Procedures; Female; Humans; Isoxazoles; Male; Middle Aged; Morphine; Pain Measurement; Pain, Postoperative; Prospective Studies; Tramadol | 2015 |
Efficacy and safety of Postoperative Intravenous Parecoxib sodium Followed by ORal CElecoxib (PIPFORCE) post-total knee arthroplasty in patients with osteoarthritis: a study protocol for a multicentre, double-blind, parallel-group trial.
Topics: Administration, Oral; Arthroplasty, Replacement, Knee; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Therapy, Combination; Humans; Injections, Intravenous; Isoxazoles; Osteoarthritis; Pain, Postoperative; Postoperative Care; Research Design; Treatment Outcome | 2016 |
Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition.
Topics: Adult; Aged; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Hyperalgesia; Isoxazoles; Mastectomy; Mastectomy, Segmental; Middle Aged; Pain Measurement; Pain Threshold; Pain, Postoperative; Perioperative Period; Prospective Studies; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2016 |
Application of a buprenorphine transdermal patch for the perioperative analgesia in patients who underwent simple lumbar discectomy.
Topics: Administration, Cutaneous; Administration, Intravenous; Administration, Oral; Analgesics, Opioid; Buprenorphine; Celecoxib; Cyclooxygenase 2 Inhibitors; Diskectomy; Female; Humans; Isoxazoles; Lumbar Vertebrae; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Patient Satisfaction; Perioperative Care; Tramadol; Transdermal Patch; Treatment Outcome | 2017 |
[EFFICACY OF SEQUENTIAL TREATMENT WITH ADDUCTOR CANAL NERVE BLOCK AND CYCLOOXYGENASE 2 SELECTIVE INHIBITOR AFTER TOTAL KNEE ARTHROPLASTY].
Topics: Analgesics, Opioid; Arthroplasty, Replacement, Knee; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Knee Joint; Morphine; Nerve Block; Operative Time; Osteoarthritis; Pain, Postoperative; Postoperative Period; Range of Motion, Articular; Treatment Outcome | 2016 |
Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Arthroplasty, Replacement, Knee; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Osteoarthritis, Knee; Pain, Postoperative; Postoperative Care; Retrospective Studies; Treatment Outcome | 2020 |
Prevention of Severe Acute Pancreatitis With Cyclooxygenase-2 Inhibitors: A Randomized Controlled Clinical Trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intravenous; Isoxazoles; Male; Middle Aged; Pancreatitis; Prospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2020 |
56 other study(ies) available for isoxazoles and celecoxib
| Article | Year |
|---|---|
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding, Competitive; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Isoenzymes; Isoxazoles; Kinetics; Meloxicam; Mice; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sheep; Sulfonamides; Thiazines; Thiazoles | 2001 |
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
Topics: Acetylation; Animals; Aspirin; Blood Platelets; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sheep; Sulfonamides; Sulfones | 2001 |
Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular System; Celecoxib; Cyclooxygenase Inhibitors; Dysmenorrhea; Female; Humans; Isoxazoles; Lactones; Male; Pyrazoles; Sulfonamides; Sulfones | 2002 |
Characterization of celecoxib and valdecoxib binding to cyclooxygenase.
Topics: Animals; Binding Sites; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Isoenzymes; Isoxazoles; Membrane Proteins; Mice; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Recombinant Proteins; Sheep; Sulfonamides; Tritium | 2003 |
Mechanism of inhibition of novel COX-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Kinetics; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Recombinant Proteins; Sulfonamides; Time Factors | 2002 |
[Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Pain; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Treatment Outcome | 2003 |
Effects of rofecoxib, celecoxib, and parecoxib on anti-IgE-induced histamine release from human skin mast cells and basophils.
Topics: Antibodies, Anti-Idiotypic; Basophils; Celecoxib; Cyclooxygenase Inhibitors; Histamine Release; Humans; Isoxazoles; Lactones; Mast Cells; Pyrazoles; Skin; Sulfonamides; Sulfones | 2003 |
Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Glioblastoma; Humans; Indomethacin; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Sulindac | 2004 |
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
Topics: Animals; Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Intraocular Pressure; Isoenzymes; Isoxazoles; Kinetics; Lactones; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rabbits; Structure-Activity Relationship; Sulfonamides; Sulfones | 2004 |
Coxibs and cardiovascular disease.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration | 2004 |
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
Topics: Animals; Antioxidants; Celecoxib; Cholesterol, LDL; Chromans; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Isoprostanes; Isoxazoles; Lactones; Meloxicam; Naproxen; Oxidation-Reduction; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles | 2004 |
Arthritis medicines and cardiovascular events--"house of coxibs".
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Humans; Isoxazoles; Pyrazoles; Sulfonamides; United States; United States Food and Drug Administration | 2005 |
Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids.
Topics: Butanones; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Nabumetone; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Sulfones | 2005 |
COX-2 inhibitors--lessons in drug safety.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Publishing; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
COX-2 inhibitors--a lesson in unexpected problems.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2005 |
Vioxx may go back on sale after scraping past FDA panel.
Topics: Celecoxib; Drug Industry; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Stroke; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
A painkiller is pulled from the market. So what do you do now?
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Isoxazoles; Nonprescription Drugs; Pyrazoles; Sulfonamides | 2004 |
Raising the safety bar--the FDA's coxib meeting.
Topics: Advertising; Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drug Labeling; Humans; Isoxazoles; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
Vioxx, Celebrex, Bextra....do we have a new target for anti-inflammatory and antipyretic therapy?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Design; Humans; Intramolecular Oxidoreductases; Isoxazoles; Lactones; Microsomes; Prostaglandin-E Synthases; Pyrazoles; Sulfonamides; Sulfones | 2005 |
New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).
Topics: Canada; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Contraindications; Cyclooxygenase Inhibitors; Decision Making; Drug Approval; Humans; Isoxazoles; Product Surveillance, Postmarketing; Pyrazoles; Risk Factors; Sulfonamides; United States; United States Food and Drug Administration | 2005 |
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Incidence; Isoxazoles; Lactones; Membrane Proteins; Meta-Analysis as Topic; Myocardial Infarction; Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
Rescuing COX-2 inhibitors from the waste bin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Endothelial Cells; Humans; Isoxazoles; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2005 |
Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection.
Topics: Animals; Celecoxib; Chromatography, High Pressure Liquid; Etoricoxib; Humans; Isoxazoles; Ketoprofen; Male; Pyrazoles; Pyridines; Rats; Rats, Wistar; Reproducibility of Results; Salicylic Acid; Spectrophotometry, Ultraviolet; Sulfonamides; Sulfones | 2006 |
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chromans; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Humans; Hypoglycemic Agents; Isoxazoles; Lactones; Myocardial Infarction; Paternalism; Platelet Aggregation Inhibitors; Pyrazoles; Sulfonamides; Sulfones; Thiazolidinediones; Troglitazone; Truth Disclosure; United States; United States Food and Drug Administration; Vasodilator Agents | 2005 |
How celecoxib could be safer, how valdecoxib might have been.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Industry; Humans; Isoxazoles; Pyrazoles; Risk Assessment; Sulfonamides; United States; United States Food and Drug Administration | 2005 |
The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II.
Topics: Acetazolamide; Anti-Inflammatory Agents, Non-Steroidal; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Isoxazoles; Pyrazoles; Structure-Activity Relationship; Sulfonamides | 2004 |
Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Isoxazoles; Lactones; Male; Middle Aged; Pyrazoles; Stevens-Johnson Syndrome; Sulfonamides; Sulfones | 2005 |
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
Topics: Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Evaluation, Preclinical; Humans; Isoenzymes; Isoxazoles; Models, Molecular; Molecular Structure; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Topoisomerase II Inhibitors | 2006 |
[Cyclooxygenase-2 inhibitors and the ethics of research].
Topics: Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Ethics, Research; Humans; Isoxazoles; Lactones; Pyrazoles; Sulfonamides; Sulfones | 2005 |
Ocular adverse effects associated with cyclooxygenase-2 inhibitors.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Conjunctivitis; Cyclooxygenase 2 Inhibitors; Etodolac; Humans; Isoxazoles; Lactones; Middle Aged; Pyrazoles; Sulfonamides; Sulfones; Vision Disorders | 2006 |
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Lactones; Marketing of Health Services; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
Reversible binding of celecoxib and valdecoxib with human serum albumin using fluorescence spectroscopic technique.
Topics: Anilino Naphthalenesulfonates; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Fluorescent Dyes; Hydrogen-Ion Concentration; Isoxazoles; Molecular Structure; Protein Binding; Pyrazoles; Serum Albumin; Spectrometry, Fluorescence; Structure-Activity Relationship; Sulfonamides; Temperature; Thermodynamics | 2006 |
The COX-2 inhibitors--an update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2006 |
How specific are "target-specific" drugs? Celecoxib as a case in point.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Isoxazoles; Lactones; Molecular Structure; Protein Binding; Pyrazoles; Sulfonamides; Sulfones | 2006 |
[Cyclooxygenase inhibitors: a never ending story?].
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Europe; Humans; Isoxazoles; Italy; Lactones; Liability, Legal; Prostaglandin-Endoperoxide Synthases; Protein Isoforms; Pyrazoles; Sulfonamides; Sulfones; Texas; United States; United States Food and Drug Administration | 2006 |
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones | 2006 |
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; Ventricular Remodeling | 2007 |
Cyclooxygenase-2 inhibition increases gastric tone and delays gastric emptying in rats.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Gastric Emptying; Gastric Mucosa; Indomethacin; Isoxazoles; Ketorolac; Lactones; Male; Muscle, Smooth; Pyrazoles; Rats; Rats, Wistar; Stomach; Sulfonamides; Sulfones | 2007 |
Coxibs: can this class of drugs survive?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Based Medicine; Half-Life; Humans; Isoxazoles; Lactones; Patient Selection; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2005 |
Preliminary development of a responder index for chronic low back pain.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic; Focus Groups; Health Status Indicators; Humans; International Cooperation; Isoxazoles; Low Back Pain; Outcome Assessment, Health Care; Pyrazoles; Reproducibility of Results; Sulfonamides | 2007 |
Orthodontic tooth movement after different coxib therapies.
Topics: Alveolar Process; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cephalometry; Cyclooxygenase 2 Inhibitors; Gingiva; Isoxazoles; Lactones; Male; Molar; Orthodontic Wires; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Sulfones; Time Factors; Tooth Movement Techniques | 2007 |
Use of cox-2 inhibitors in patients with retinal venous occlusive disease.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Utilization; Female; Humans; Isoxazoles; Lactones; Male; Middle Aged; Prevalence; Pyrazoles; Retinal Vein Occlusion; Retrospective Studies; Sulfonamides; Sulfones | 2008 |
Crunch time for peer review in lawsuit.
Topics: Celecoxib; Confidentiality; Drug Industry; Humans; Isoxazoles; Peer Review, Research; Periodicals as Topic; Pyrazoles; Sulfonamides; United States | 2008 |
Preserving confidentiality in the peer review process.
Topics: Advertising; Celecoxib; Confidentiality; Cyclooxygenase 2 Inhibitors; Disclosure; Drug Industry; Isoxazoles; Liability, Legal; Peer Review, Research; Pyrazoles; Sulfonamides; United States | 2008 |
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Follow-Up Studies; Humans; Isoxazoles; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Osteoarthritis; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; United States | 2008 |
The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Resorption; Celecoxib; Cell Growth Processes; Cell Survival; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Humans; Indomethacin; Isoxazoles; Macrophage Colony-Stimulating Factor; Osteoclasts; Pyrazoles; RANK Ligand; Stem Cells; Sulfonamides; Time Factors | 2009 |
Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Humans; Incidence; Isoxazoles; Lactones; Logistic Models; Middle Aged; Odds Ratio; Pyrazoles; Risk; Sulfonamides; Sulfones | 2011 |
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis | 2010 |
Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
Topics: Aged; Arm; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Eruptions; Etoricoxib; Female; Humans; Isoxazoles; Leg Dermatoses; Low Back Pain; Patch Tests; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2012 |
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones | 2016 |
The efficacy of a multimodal analgesia protocol in preventing heterotopic ossification after acetabular fractures surgery.
Topics: Acetabulum; Adult; Aged; Analgesia; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Fractures, Bone; Humans; Isoxazoles; Male; Middle Aged; Ossification, Heterotopic; Pain Management; Pain, Postoperative; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Radiosynthesis and in vivo evaluation of [
Topics: Animals; Brain; Carbon Radioisotopes; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Isoxazoles; Male; Molecular Structure; Papio; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Sulfonamides | 2018 |
Copper-Catalyzed Reductive Ring-Cleavage of Isoxazoles: Synthesis of Fluoroalkylated Enaminones and Application for the Preparation of Celecoxib, Deracoxib, and Mavacoxib.
Topics: Catalysis; Celecoxib; Copper; Isoxazoles; Pyrazoles; Sulfonamides | 2021 |
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway | 2021 |
Perioperative Outcomes of Patients Who Were Not Candidates for Additional Nonsteroidal Anti-inflammatory Drugs in a Multimodal Pain Control Regimen for Total Knee Arthroplasty.
Topics: Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Knee; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Isoxazoles; Male; Middle Aged; Morphine; Pain Management; Pain Measurement; Pain, Postoperative; Retrospective Studies | 2021 |